Noveome is developing ST266, a first-in-man, first-in-class “cell therapy without the cell” to treat a wide range of serious diseases and conditions.
ST266 is a complex non-cellular drug that contains hundreds of biologically active proteins and other biologic factors crucial to cellular healing and modulating inflammation. These biologically active proteins and factors are delivered in physiological concentrations that have been shown to be well-tolerated with proven biological activity in preclinical and clinical studies.
Unlike genetically engineered cellular products, ST266 is made by our proprietary method of culturing amnion cells that are harvested from full term placenta that is normally discarded after birth. These cells produce many of the biologic factors found in amniotic fluid that promote healing, restore nerve damage, and are anti-inflammatory.
ST266 demonstrates the following unique attributes, which can be applied across a wide range of disease indications to improve patient outcomes.
Speeds Impaired Wound Healing
Restores Nerve Function
Strong Safety Profile
Noveome Biotherapeutics, Inc. Announces the First Patient Dosed in Phase 2 Open Label Clinical Trial Evaluating Topical Ocular Delivery of ST266 For the Treatment of Persistent Corneal Epithelial DefectsFull Story
Noveome Biotherapeutics, Inc. Announces Publication of Further Preclinical Results Supporting the Neuroprotective Properties of ST266 in Retinal Ganglion CellsFull Story
Noveome Biotherapeutics, Inc. Completes $15 Million Series D Financing to Advance Growing Pipeline of Next-Generation BiologicsFull Story